RF ablation patients are 10x more likely to progress to persistent AF/AT compared with antiarrhythmic drugs based treatment

Intervene early to delay disease progression

Early AF ablation can mean patients are less likely to develop persistent AF, leading to successful results over time.1

Biosense Webster – AF Ablation STSF VIZIGO VISITAG

Optimize your treatment approach

When patients need more than PVI, Biosense Webster technology allows for a patient-tailored approach.2

Atrial Fibrillation Catheter Ablation Patient

Deliver lasting impact

Our technology and workfows help you achieve long-term outcomes that keep your patients living their best lives possible.2†


 * In a prospective, multicenter, randomized, controlled 2-arm study (ATTEST, n=255). Cox model with multiple baseline covariates and treatment as the time-dependent covariate determined hazard ratio:
0.107 (95% CI: 0.024–0.47; P=0.0031).
† Long-term outcomes of clinical success rate of 80% at 15 months.
1. Kuck K-H, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: The randomized controlled Atrial Fibrillation Progression Trial (ATTEST).
Europace. 2021;23(3):362-369.
2. Mansour M, Calkins H, Osorio J et al. Persistent atrial fibrillation ablation with contact force sensing catheter: The prospective multicenter PRECEPT Trial. JACC Clin Electrophysiol. 2020;6(8):958-969.

The THERMOCOOL SMARTTOUCH® SF Catheter is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (AF) and for drug refractory recurrent symptomatic persistent AF (continuous AF > 7 days but < 1 year), refractory or intolerant to at least 1 Class I or III AAD, when used with the CARTO® 3 System.

173700-210413 ©Biosense Webster, Inc. 2021 Last Updated on 4/13/2021.